Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial

JAMA Otolaryngol Head Neck Surg. 2021 Apr 1;147(4):400-401. doi: 10.1001/jamaoto.2020.5490.

Abstract

This randomized clinical trial investigates the efficacy of nasopharyngeal povidone iodine solutions in reducing the viral load of patients with COVID-19.

Trial registration: ClinicalTrials.gov NCT04371965.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Infective Agents, Local / administration & dosage*
  • Anti-Infective Agents, Local / adverse effects
  • COVID-19 / virology*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Mouthwashes*
  • Nasal Sprays*
  • Nasopharynx / virology*
  • Povidone-Iodine / administration & dosage*
  • Povidone-Iodine / adverse effects
  • SARS-CoV-2
  • Thyrotropin / blood
  • Thyrotropin / drug effects
  • Viral Load*

Substances

  • Anti-Infective Agents, Local
  • Mouthwashes
  • Nasal Sprays
  • Povidone-Iodine
  • Thyrotropin

Associated data

  • ClinicalTrials.gov/NCT04371965